10-QPeriod: Q3 FY2004

ALNYLAM PHARMACEUTICALS, INC. Quarterly Report for Q3 Ended Sep 30, 2004

Filed November 15, 2004For Securities:ALNY

Summary

This 10-Q filing for ALNYLAM PHARMACEUTICALS, INC. (ALNY) as of and for the period ending September 30, 2004, provides an update on the company's financial position and operational results. Investors should note that as a development-stage biopharmaceutical company, ALNY is primarily focused on research and development, with revenue generation likely still in the future. The financial statements, including the balance sheet, statements of operations, and cash flows, will offer insight into the company's burn rate, funding status, and progress in its therapeutic programs. The Management's Discussion and Analysis (MD&A) section is crucial for understanding the narrative behind the numbers, including the company's strategic objectives, clinical trial progress, and potential risks and opportunities.

Key Highlights

  • 1The filing contains unaudited interim consolidated financial statements, including balance sheets, statements of operations, and cash flows for the nine months ended September 30, 2004.
  • 2Investors can assess ALNY's cash position and its ability to fund ongoing research and development activities through the consolidated balance sheets and statements of cash flows.
  • 3The statements of operations will detail the company's revenue (likely minimal at this stage) and significant operating expenses, primarily research and development costs.
  • 4Management's Discussion and Analysis (MD&A) provides crucial context on the company's financial condition, results of operations, and future outlook.
  • 5The report includes disclosures on market risks and information regarding controls and procedures, offering insights into the company's operational integrity and risk management strategies.
  • 6Disclosure of unregistered sales of equity securities and use of proceeds can shed light on the company's financing activities and capital structure.

Frequently Asked Questions

The financial statements, particularly the balance sheets and statements of cash flows, will detail the company's cash and cash equivalents, as well as its net cash used in operating activities. This will allow investors to estimate the company's monthly or quarterly 'burn rate' and assess its runway for continued operations and R&D.

The statements of operations will show significant expenses related to research and development. The MD&A section is key to understanding the specific R&D programs, their stage of development, and potential timelines for clinical trials and eventual product commercialization, which will drive future revenue.

Item 2 under Part II, 'Unregistered Sales of Equity Securities and Use of Proceeds,' will provide information on any recent equity financings, including the amount of securities sold and how the proceeds have been or will be utilized. This is important for understanding potential dilution and capital needs.

The MD&A and the 'Quantitative and Qualitative Disclosures About Market Risk' sections are essential for identifying the primary risks. These typically include risks associated with drug development (clinical trial failures, regulatory hurdles), competition, intellectual property, and the company's ability to secure future funding.